$IONS News
Last published 2d ago
- 2d agoIONSWolf Popper LLP Announces Investigation on Behalf of Ionis Pharmaceuticals, Inc. InvestorsGlobeNewswireNEW YORK, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of Ionis Pharmaceuticals, Inc. (Ionis) common stock (NASDAQ: IONS).
- 2d agoIONSIonis presents new long-term data supporting durable efficacy and disease control with DAWNZERA® (donidalorsen) at ACAAI 2026 Annual MeetingBusiness WireCARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new long-term data for DAWNZERA® (donidalorsen), the first and only RNA-targeted medicine for hereditary angioedema (HAE), to be presented at the 2026 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Phoenix, Arizona. Multiple presentations will demonstrate the long-te ...
- 4d agoIONSWolf Popper LLP Announces Investigation on Behalf of Ionis Pharmaceuticals, Inc. InvestorsGlobeNewswireNEW YORK, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Wolf Popper LLP is investigating potential claims on behalf of purchasers of Ionis Pharmaceuticals, Inc. (Ionis) common stock (NASDAQ: IONS).
- 4d agoIONSIonis to present at upcoming investor conferencesBusiness WireCARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: UBS Global Biopharma Conference on Monday, November 16, 2026 Jefferies Global Healthcare Conference on Wednesday, November 18, 2026 Citi’s 2026 Global Healthcare Conference on Tuesday, December 1, 2026 Piper Sandler ...
- 5d agoIONSIONIS PHARMACEUTICALS INC - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 5d agoIONSIonis reports third quarter 2026 financial results and highlights progress on key programsBusiness WireCARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the third quarter ended September 30, 2026. “In 2026, we continue to advance innovative medicines for people with serious diseases, underscored by three approvals for groundbreaking first-in-class medicines, two of which are Ionis-owned,” said ...
- 3w agoIONSIonis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN)Business Wire– Sefaxersen achieved a statistically significant 43.1% reduction in proteinuria, a key indicator of kidney damage, relative to placebo at 37 weeks with consistent treatment effects across all prespecified patient
- 3w agoIONSIonis ranked #1 on Science’s Top Employers listBusiness WireIonis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that the company was named the top employer to work for by Science in its annual Top Employers survey of the biotech and pharmaceutical industries. Rising from
- 3w agoIONSIonis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)Business Wire– Approval based on Phase 3 data showing unprecedented functional cure rates compared to standard of care – – Six-month treatment with option of at-home administration after first dose – – CHB affects approximately 1.7
- 4w agoIONSTRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)Business WireIonis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the indication
- 1mo agoIONSIonis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)Business Wire– Sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential – – IgAN is a progressive kidney disease that is
- 1mo agoIONSIonis announces positive topline results from Phase 3 FUSION study of ulefnersen marking significant milestone in advancing first potential disease modifying treatment for FUS-ALSBusiness Wire– Ulefnersen demonstrated a statistically significant improvement on the primary endpoint assessing functional impairment and survival in people living with FUS-ALS, supporting the potential to modify disease
- 1mo agoIONSMorgan Stanley 24th Annual Global Healthcare Conference - IONIS PHARMACEUTICALS INCEarnings Call TranscriptsAll right, good morning, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Galtz, one of the biotech analysts, and it's my pleasure to introduce Brett Moina, CEO of Ionis Ph
- 1mo agoIONSMorgan Stanley 24th Annual Global Healthcare Conference - IONIS PHARMACEUTICALS INCEarnings Call TranscriptsAll right, good morning, everyone, and thanks for joining us at the Morgan Stanley Global Healthcare Conference. I'm Mike Galtz, one of the biotech analysts, and it's my pleasure to introduce Brett Moina, CEO of Ionis Ph
- 2mo agoIONSIONIS PHARMACEUTICALS, INC. - WELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - IONIS PHARMACEUTICALS INCEarnings Call TranscriptsOkay, thanks everyone for being here. My name is Yanen Zhu. I'm one of the biotech analysts here at Wells Fargo. It is my great pleasure to be joined by Brett Monia, CEO of Ionis Pharmaceuticals. Thank you, Brett, for be
- 2mo agoIONSWELLS FARGO 21ST ANNUAL HEALTHCARE CONFERENCE - IONIS PHARMACEUTICALS INCEarnings Call TranscriptsOkay, thanks everyone for being here. My name is Yanen Zhu. I'm one of the biotech analysts here at Wells Fargo. It is my great pleasure to be joined by Brett Monia, CEO of Ionis Pharmaceuticals. Thank you, Brett, for be
- 2mo agoNVSIONSAMGNLLY+1Cholesterol drug setback casts doubt over multibillion-dollar raceCNBCNovartis’ failure raises the stakes for Amgen and Eli Lilly in the race to turn lower Lp(a) levels into fewer heart attacks and strokes.
- 2mo agoIONSIonis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)Business WireIonis Pharmaceuticals, Inc. (NASDAQ:IONS) partner Novartis today announced that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes trial, did not meet its primary endpoint of reducing the
- 2mo agoIONSZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patientsBusiness Wire- Provides a clinically meaningful impact on motor function and a favorable impact on other symptoms seen in AxD, an ultra-rare, progressive and often fatal neurological disorder - - Priority Review Voucher (PRV)
- 2mo agoIONSIonis to present at upcoming investor conferencesBusiness WireIonis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that management will participate in fireside chats at the following investor conferences: 21st Annual Wells Fargo Healthcare Conference on Thursday,
- 2mo agoIONSApproval of Zanvastro, Nda #220210 (Type 1 - New Molecular Entity)FDA Approved DrugsApproval Date: 09/03/2026; Drug Name: Zanvastro, Nda #220210; Active Ingredients: ZILGANERSEN; Company: Ionis Pharms Inc; Submission Status: Approval; Submission Classification: Type 1 - New Molecular Entity; Application Number: 220210
- 2mo agoIONSFDA Approves First Drug to Treat Alexander DiseaseFDA Press ReleasesThe U.S. Food and Drug Administration has approved Zanvastro (zilganersen) injection for the treatment of Alexander disease in pediatric and adult patients. Zanvastro is the first FDA-approved treatment for Alexander disease and the first therapy to directly target the protein buildup that drives the disease.“For patients with Alexander disease and their families, there have been no approved treat ...
- 2mo agoIONSIonis to present new data strengthening leadership in the management of severe hypertriglyceridemia (sHTG) at the European Society of Cardiology Congress 2026Business WireIonis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that new data in the management of severe hypertriglyceridemia (sHTG) will be presented at the European Society of Cardiology (ESC) Congress 2026, taking place
- 3mo agoIONSIonis announces Dr. Frank Bennett, chief scientific officer, to retireBusiness WireIonis Pharmaceuticals, Inc. (NASDAQ:IONS) announced today that Frank Bennett, Ph.D., executive vice president and chief scientific officer, will retire effective February 2027."As a founding scientist, Frank has
- 3mo agoIONSIonis reports second quarter 2026 financial results and highlights progress on key programsBusiness Wire- TRYNGOLZA® (olezarsen) demonstrating early sHTG launch momentum, underscoring multi-billion-dollar revenue potential in large patient population – - Completed enrollment in Phase 3 REVEAL trial in Angelman syndrome
- 3mo agoIONSIonis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSSGlobeNewswireSAN FRANCISCO, July 28, 2026 (GLOBE NEWSWIRE) -- Investors in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) saw the price of their shares plunge $20.19 (-23%) on July 9, 2026 after the commercial stage biotech company and
- 3mo agoIONSIonis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% - HBSSPR NewswireInvestors in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) saw the price of their shares plunge $20.19 (-23%) on July 9, 2026 after the commercial stage ...
- 4mo agoIONSIonis to hold second quarter 2026 financial results webcastBusiness WireWebcast scheduled for Wednesday, July 29 at 8:30 a.m. Eastern TimeIonis Pharmaceuticals, Inc. (NASDAQ:IONS) announced today that it will host a live webcast on Wednesday, July 29 at 8:30 a.m. Eastern Time to discuss its
- 4mo agoIONSIonis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSSGlobeNewswireSAN FRANCISCO, July 14, 2026 (GLOBE NEWSWIRE) -- Investors in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) saw the price of their shares plunge $20.19 (-23%) on July 9, 2026 after the commercial stage biotech company and
- 4mo agoIONSIonis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s DiseaseBusiness Wire- Clinical outcomes: Diranersen demonstrated efficacy across all studied doses at 18 months, with consistent results across multiple prespecified clinical endpoints; the 60 mg dose showed the strongest response with
- 4mo agoIONSIonis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndromeBusiness WireIonis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that the first participant has been dosed in the Phase 1-2 ASCEND study of ION337, an investigational RNA-targeted medicine for people living with Dravet
- 4mo agoIONSUpdate on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathyBusiness Wire– Study missed primary endpoint of composite outcome of cardiovascular (CV) mortality and recurrent CV events; in a pre-specified subgroup analysis, a nominally significant result was observed with eplontersen
- 4mo agoIONSIonis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndromeBusiness Wire- Topline data from REVEAL anticipated in 2H 2027 - Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that it has completed enrollment in the pivotal cohort (Cohort 1) of the global Phase 3 REVEAL study
- 4mo agoIONSIonis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.Business Wire- Recordati brings deep rare disease expertise and proven capabilities in commercialization, access and country-specific regulatory environments - - Ionis to independently commercialize zilganersen in the U.S.
- 4mo agoIONSTRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)Business Wire– Proven to deliver significant and robust triglyceride reductions – – Only treatment for sHTG indicated to reduce the risk of acute pancreatitis – – Ionis’ first independent commercial launch in a prevalent
- 4mo agoIONSApproval of Tryngolza (autoinjector), Nda #218614 (Efficacy)FDA Approved DrugsApproval Date: 06/24/2026; Drug Name: Tryngolza (autoinjector), Nda #218614; Active Ingredients: OLEZARSEN SODIUM; Company: Ionis Pharms Inc; Submission Status: Approval; Submission Classification: Efficacy; Application Number: 218614
- 5mo agoIONSIonis announces appointment of Ludwig Hantson, Ph.D. to Board of DirectorsBusiness WireIonis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced the appointment of Ludwig Hantson, Ph.D., an accomplished global biopharmaceutical leader, to the Ionis Board of Directors, effective immediately."We are pleased
- 5mo agoIONSIonis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congressesBusiness WireIonis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that new data analyses from the landmark Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypertriglyceridemia (sHTG) will be presented during
- 5mo agoIONSIonis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis BBusiness Wire– Pivotal B-Well data show significant 19% functional cure rate in the overall study population and 26% in patients with lower viral activity, compared to 0% with standard of care – – 49% of bepirovirsen recipients
- 6mo agoIONSIonis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer's diseaseBusiness Wire- Based on the strength of the biomarker and efficacy data, Biogen plans to advance diranersen to registrational development; CELIA did not meet its primary endpoint assessing dose response - - Robust reductions in
- 6mo agoIONSIonis to host 2026 virtual Annual Meeting of StockholdersBusiness WireIonis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that management will conduct its 2026 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 4, 2026. The agenda for
- 6mo agoIONSIonis to present at upcoming investor conferencesBusiness WireIonis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that management will participate in fireside chats at the following investor conferences: Bank of America Securities 2026 Health Care Conference on Tuesday,
- 6mo agoIONSIonis reports first quarter 2026 financial results and highlights progress on key programsBusiness Wire- TRYNGOLZA® (olezarsen) showed increasing demand in FCS driven by strong launch execution – - Olezarsen sNDA accepted by the FDA for Priority Review; sHTG launch preparations on track – – Increasing annual
- 6mo agoIONSIonis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis BBusiness Wire– Regulatory submission supported by Phase 3 B-Well trials demonstrating statistically significant and clinically meaningful functional cure rates in chronic hepatitis B - – Breakthrough Therapy designation added to
- 6mo agoIONSIonis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual MeetingBusiness Wire– New data highlight potential treatment benefit across multiple AxD symptom domains, reinforcing zilganersen's positive impact on people living with this rare, often fatal neurological disease – – PDUFA date set for
- 7mo agoIONSIonis to hold first quarter 2026 financial results webcastBusiness WireWebcast scheduled for Wednesday, April 29 at 8:30 a.m. Eastern Time Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) announced today that it will host a live webcast on Wednesday, April 29 at 8:30 a.m. Eastern Time to
- 7mo agoBIIBIONSFDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular AtrophyGlobeNewswireThe approval was anchored on data from the pivotal DEVOTE study that investigated the efficacy and safety of the High Dose Regimen of SPINRAZA in treatment-naïve and previously treated SPINRAZA patientsHigh Dose SPINRAZA
- 7mo agoIONSIonis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority ReviewBusiness Wire– PDUFA date set for September 22, 2026 – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for
- 8mo agoIONSIonis announces changes to Board of DirectorsBusiness Wire– Lynne Parshall and Joseph Wender to retire at end of term in June 2026 and Peter Reikes to join Ionis Board – Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) today announced upcoming transitions on its Board of Directors.
- 8mo agoBIIBIONSBiogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe ConferencesGlobeNewswireLong-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA)New Phase 1b data further illustrate potential of salanersen in SMA, as Phase 3 studies